Full Press Release Details
Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies
CA, February 26, 2024 - LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company")
today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke
(NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
the terms of the license agreement, LIXTE has licensed exclusively NIH's intellectual property rights claimed for a Cooperative
Research and Development Agreement (CRADA) subject invention co-developed with Lixte, and the licensed field of use, which focuses on
promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends
to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
strategic collaboration marks a significant milestone in advancing LIXTE's mission to advance cancer therapy by developing its
first-in-class lead clinical PP2A inhibitor, LB-100, as a potentiator of cancer immunotherapy," said Bas van der Baan, Chief Executive
Officer of LIXTE. "We are excited to embark on this journey as it opens up new avenues for advancing our commitment to developing
effective and targeted anti-cancer therapies. The agreement reinforces our dedication to pioneering research and delivering innovative
solutions to patients battling cancer," he added.
collaboration harnesses the synergies of LIXTE's innovative compound, LB-100, and NINDS's and NCI's cutting-edge research
capabilities. The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that
can potentially transform the landscape of cancer treatment.
recently announced the entry of the first patient into a Phase 1b/2 clinical trial to assess whether adding LIXTE's LB-100 to GSK's
programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, has the ability to enhance the effectiveness of
immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). Another Phase 1b clinical trial in small cell lung cancer combining
LB-100 with Roche's atezolizumab and chemotherapy is also actively recruiting. The Company intends to develop additional clinical
trials with LB-100 to enhance the efficacy of chemotherapy and immunotherapy.
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE's
new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress.
Statement Disclaimer
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing
development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal
costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain
compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied
by words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other comparable terminology.
Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have
been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general
are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission
at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
more information about LIXTE, Contact: info@lixte.com
Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Inc. Investor Relations
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962